Literature DB >> 22138747

Melatonin pathway genes and breast cancer risk among Chinese women.

Sandra L Deming1, Wei Lu, Alicia Beeghly-Fadiel, Ying Zheng, Qiuyin Cai, Jirong Long, Xiao Ou Shu, Yu-Tang Gao, Wei Zheng.   

Abstract

Previous studies suggest that melatonin may act on cancer growth through a variety of mechanisms, most notably by direct anti-proliferative effects on breast cancer cells and via interactions with the estrogen pathway. Three genes are largely responsible for mediating the downstream effects of melatonin: melatonin receptors 1a and 1b (MTNR1a and MTNR1b), and arylalkylamine N-acetyltransferase (AANAT). It is hypothesized that genetic variation in these genes may lead to altered protein production or function. To address this question, we conducted a comprehensive evaluation of the association between common single nucleotide polymorphisms (SNPs) in the MTNR1a, MTNR1b, and AANAT genes and breast cancer risk among 2,073 cases and 2,083 controls, using a two-stage analysis of genome-wide association data among women of the Shanghai Breast Cancer Study. Results demonstrate two SNPs were consistently associated with breast cancer risk across both study stages. Compared with MTNR1b rs10765576 major allele carriers (GG or GA), a decreased risk of breast cancer was associated with the AA genotype (OR = 0.78, 95% CI = 0.62-0.97, P = 0.0281). Although no overall association was seen in the combined analysis, the effect of MTNR1a rs7665392 was found to vary by menopausal status (P-value for interaction = 0.001). Premenopausal women with the GG genotype were at increased risk for breast cancer compared with major allele carriers (TT or TG) (OR = 1.57, 95% CI = 1.07-2.31, P = 0.020), while postmenopausal women were at decreased risk (OR = 0.58, 95% 0.36-0.95, P = 0.030). No significant breast cancer associations were found for variants in the AANAT gene. These results suggest that common genetic variation in the MTNR1a and 1b genes may contribute to breast cancer susceptibility, and that associations may vary by menopausal status. Given that multiple variants in high linkage disequilibrium with MTNR1b rs76653292 have been associated with altered function or expression of insulin and glucose family members, further research may focus on clarifying this relationship.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138747      PMCID: PMC3777385          DOI: 10.1007/s10549-011-1884-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  31 in total

1.  Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines.

Authors:  Oliver Treeck; Chandana Haldar; Olaf Ortmann
Journal:  Oncol Rep       Date:  2006-01       Impact factor: 3.906

Review 2.  Melatonin in humans.

Authors:  A Brzezinski
Journal:  N Engl J Med       Date:  1997-01-16       Impact factor: 91.245

3.  Positive relationship between melatonin receptor type 1B polymorphism and rheumatoid factor in rheumatoid arthritis patients in the Korean population.

Authors:  Eunyoung Ha; Bong-Keun Choe; Kyung Hee Jung; Seo Hyun Yoon; Hae Jeong Park; Hun Kuk Park; Sung-Vin Yim; Joo-Ho Chung; Hyun-Su Bae; Min Nam; Hyung Hwan Baik; Seung-Jae Hong
Journal:  J Pineal Res       Date:  2005-09       Impact factor: 13.007

Review 4.  The pineal gland: a neurochemical transducer.

Authors:  J Axelrod
Journal:  Science       Date:  1974-06-28       Impact factor: 47.728

5.  Photoneural regulation of the mammalian pineal gland.

Authors:  D C Klein
Journal:  Ciba Found Symp       Date:  1985

6.  The role of melatonin receptor 1B gene (MTNR1B) in adolescent idiopathic scoliosis--a genetic association study.

Authors:  X S Qiu; N L Tang; H Y Yeung; Y Qiu; L Qin; K M Lee; J C Y Cheng
Journal:  Stud Health Technol Inform       Date:  2006

7.  Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study.

Authors:  Y T Gao; X O Shu; Q Dai; J D Potter; L A Brinton; W Wen; T A Sellers; L H Kushi; Z Ruan; R M Bostick; F Jin; W Zheng
Journal:  Int J Cancer       Date:  2000-07-15       Impact factor: 7.396

8.  Genetic differences in human circadian clock genes among worldwide populations.

Authors:  Christopher M Ciarleglio; Kelli K Ryckman; Stein V Servick; Akiko Hida; Sam Robbins; Nancy Wells; Jennifer Hicks; Sydney A Larson; Joshua P Wiedermann; Krista Carver; Nalo Hamilton; Kenneth K Kidd; Judith R Kidd; Jeffrey R Smith; Jonathan Friedlaender; Douglas G McMahon; Scott M Williams; Marshall L Summar; Carl Hirschie Johnson
Journal:  J Biol Rhythms       Date:  2008-08       Impact factor: 3.182

9.  Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice.

Authors:  A Collins; L Yuan; T L Kiefer; Q Cheng; L Lai; S M Hill
Journal:  Cancer Lett       Date:  2003-01-10       Impact factor: 8.679

10.  Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells.

Authors:  A González; C Martínez-Campa; M D Mediavilla; C Alonso-González; S Sánchez-Mateos; S M Hill; E J Sánchez-Barceló; S Cos
Journal:  Oncol Rep       Date:  2007-04       Impact factor: 3.906

View more
  17 in total

1.  Urinary Melatonin in Relation to Postmenopausal Breast Cancer Risk According to Melatonin 1 Receptor Status.

Authors:  Elizabeth E Devore; Erica T Warner; A Heather Eliassen; Susan B Brown; Andrew H Beck; Susan E Hankinson; Eva S Schernhammer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-11-09       Impact factor: 4.254

2.  Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature.

Authors:  Michelle Basler; Alexander Jetter; Daniel Fink; Burkhardt Seifert; Gerd A Kullak-Ublick; Andreas Trojan
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

3.  Interactions between environmental factors and melatonin receptor type 1A polymorphism in relation to oral cancer susceptibility and clinicopathologic development.

Authors:  Feng-Yan Lin; Chiao-Wen Lin; Shun-Fa Yang; Wei-Jiunn Lee; Yung-Wei Lin; Liang-Ming Lee; Junn-Liang Chang; Wei-Chun Weng; Chien-Huang Lin; Ming-Hsien Chien
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

Review 4.  Melatonin for the prevention and treatment of cancer.

Authors:  Ya Li; Sha Li; Yue Zhou; Xiao Meng; Jiao-Jiao Zhang; Dong-Ping Xu; Hua-Bin Li
Journal:  Oncotarget       Date:  2017-06-13

Review 5.  Melatonin as a potential inhibitory agent in head and neck cancer.

Authors:  Chia-Ming Yeh; Shih-Chi Su; Chiao-Wen Lin; Wei-En Yang; Ming-Hsien Chien; Russel J Reiter; Shun-Fa Yang
Journal:  Oncotarget       Date:  2017-08-09

6.  Night-shift work, circadian and melatonin pathway related genes and their interaction on breast cancer risk: evidence from a case-control study in Korean women.

Authors:  Thu-Thi Pham; Eun-Sook Lee; Sun-Young Kong; Jeongseon Kim; Sun-Young Kim; Jungnam Joo; Kyong-Ah Yoon; Boyoung Park
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

7.  Association of Melatonin Pathway Gene's Single-Nucleotide Polymorphisms with Systemic Lupus Erythematosus in a Chinese Population.

Authors:  Peng Wang; Lei Liu; Li-Fang Zhao; Chan-Na Zhao; Yan-Mei Mao; Yi-Lin Dan; Qian Wu; Xiao-Mei Li; De-Guang Wang; Hai-Feng Pan
Journal:  J Immunol Res       Date:  2019-11-13       Impact factor: 4.818

Review 8.  Role of Melatonin in the Regulation of Pain.

Authors:  Shanshan Xie; Wenguo Fan; Hongwen He; Fang Huang
Journal:  J Pain Res       Date:  2020-02-07       Impact factor: 3.133

Review 9.  Melatonin receptor genes in vertebrates.

Authors:  Di Yan Li; David Glenn Smith; Rüdiger Hardeland; Ming Yao Yang; Huai Liang Xu; Long Zhang; Hua Dong Yin; Qing Zhu
Journal:  Int J Mol Sci       Date:  2013-05-27       Impact factor: 5.923

10.  Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study.

Authors:  Cecilia Bosco; Wahyu Wulaningsih; Jennifer Melvin; Aida Santaolalla; Mario De Piano; Rhonda Arthur; Mieke Van Hemelrijck
Journal:  Ecancermedicalscience       Date:  2015-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.